Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Atsou, Kokuvi ^a,b   Chouaid, Christos ^a,b,c   Hejblum, Gilles ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; HIDDEN MARKOV MODEL; LIFE EXPECTANCY; MONTE CARLO METHOD; QUALITY ADJUSTED LIFE YEAR; RELAPSE; SMOKING CESSATION PROGRAM; UNITED KINGDOM; ADULT; AGED; BIOLOGICAL MODEL; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; FRANCE; HUMAN; MIDDLE AGED; MORTALITY; PROBABILITY; SMOKING CESSATION;

ADULT; AGED; AGED, 80 AND OVER; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FRANCE; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION;

EID: 80052825086     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024870     Document Type: Article

References (35)

1. Mathers CD, Loncar D, (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
2. Mannino DM, Buist AS, (2007) Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370: 765-773.
3. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, et al. (2000) Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 161: 381-390.
4. Christakis NA, Fowler JH, (2008) The collective dynamics of smoking in a large social network. N Engl J Med 358: 2249-2258.
5. Goodman PG, Haw S, Kabir Z, Clancy L, (2009) Are there health benefits associated with comprehensive smoke-free laws. Int J Public Health 54: 367-378.
6. Orleans CT, Jepson C, Resch N, Rimer BK, (1994) Quitting motives and barriers among older smokers. The 1986 Adult Use of Tobacco Survey revisited. Cancer 74: 2055-2061.
7. Shahab L, Jarvis MJ, Britton J, West R, (2006) Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 61: 1043-1047.
8. Parrott S, Godfrey C, (2004) Economics of smoking cessation. BMJ 328: 947-949.
9. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP, (2010) Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 65: 711-718.
10. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, van Genugten ML, Buist AS, et al. (2005) A dynamic population model of disease progression in COPD. Eur Respir J 26: 223-233.
11. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal. Available: http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal.jsp. Accessed july 2010.
12. Siegel JE, Weinstein MC, Russell LB, Gold MR, (1996) Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276: 1339-1341.
13. Sonnenberg FA, Beck JR, (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13: 322-338.
14. Global Initiative for Chronic Obstructive Lung Disease (2009) Global strategy for the Diagnosis. Management. and Prevention of Chronic Obstructive Pulmonary Disease: updated. Available: http://www.goldcopd.com/download.asp?intId=554. Accessed July 2010.
15. Lindberg A, Bjerg A, Ronmark E, Larsson LG, Lundback B, (2006) Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 100: 264-272.
16. Office For National Statistics (2008) Population Estimates for England Mid Year 2008. Available: http://www.statistics.gov.uk/downloads/theme_population/mid-2008-improved-migration-revised-13-05-10.zip. Accessed August 2010.
17. Nielsen R, Johannessen A, Benediktsdottir B, Gislason T, Buist AS, et al. (2009) Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J 34: 850-857.
18. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, et al. (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60: 925-931.
19. Eurostat (2007) European statistic database. Available: http://epp.eurostat.ec.europa.eu/portal/page/portal/health/public_health/database. Accessed July 2010.
20. Mannino DM, Doherty DE, Sonia Buist A, (2006) Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 100: 115-122.
21. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Lofdahl CG, (2005) Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 6: 98.
22. Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson E, et al. (2002) Costs of COPD in Sweden according to disease severity. Chest 122: 1994-2002.
23. The Economist (2010) The Economist's Big Mac index. Big Mac index. Available: http://www.economist.com/markets/bigmac/. Accessed July 2010.
24. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, et al. (2004) A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 7: 153-167.
25. Doll R, Peto R, Boreham J, Sutherland I, (2004) Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328: 1519.
26. Stead LF, Perera R, Bullen C, Mant D, Lancaster T, (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev pp. CD000146.
27. Taylor DC, Chu P, Rosen VM, Baker CL, Thompson D, (2009) Budgetary impact of varenicline in smoking cessation in the United Kingdom. Value Health 12: 28-33.
28. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, et al. (2009) Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J 34: 634-640.
29. Tonnesen P, Mikkelsen K, Bremann L, (2006) Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 130: 334-342.
30. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, et al. (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272: 1497-1505.
31. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP, (2005) Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 165: 2286-2292.
32. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP, (2001) The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 164: 590-596.
33. Jensen HH, Godtfredsen NS, Lange P, Vestbo J, (2006) Potential misclassification of causes of death from COPD. Eur Respir J 28: 781-785.
34. Mannino DM, Kiriz VA, (2006) Changing the burden of COPD mortality. Int J Chron Obstruct Pulmon Dis 1: 219-233.
35. Atsou K, Chouaid C, Hejblum G, (2011) Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med 9: 7.